AstraZeneca's Ultomiris hits primary endpoint in rare kidney disease trial

AstraZeneca PLC's (LSE:AZN, NASDAQ:AZN) Ultomiris has met its primary endpoint in a phase III trial targeting immunoglobulin A nephropathy (IgAN), a rare...